Cosmo Pharma Slips To Loss In FY25 On Weak Revenues; Stock Drops

Cosmo Pharmaceuticals reported a fiscal 2025 loss (versus a profit in the prior year) on sharply lower revenues, and its shares fell about 14% in Swiss morning trading. The results represent a material deterioration in company fundamentals and are likely to weigh on near-term investor sentiment for the stock.

Analysis

Cosmo Pharmaceuticals reported a fiscal 2025 loss (versus a profit in the prior year) on sharply lower revenues, and its shares fell about 14% in Swiss morning trading. The results represent a material deterioration in company fundamentals and are likely to weigh on near-term investor sentiment for the stock.